Sirona Medical Raises $40M Series D as Platform Usage Triples
Round led by Avidity Partners. Platform usage, ARR, & contracted ARR all grew by more than 2.5x year-over-year.…
New composite outcomes data show patients treated with Lilly’s Omvoh (mirikizumab-mrkz) achieved comprehensive corticosteroid-free disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn’s disease at one year
In LUCENT-2, more than one in four (27.7%) Omvoh-treated patients with ulcerative colitis achieved comprehensive disease control, a…
Lilly’s triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes
In TRIUMPH-2, participants with obesity and type 2 diabetes taking retatrutide 12 mg lost an average of 49.6…
Oracle and Buck Institute for Research on Aging Advance Landmark Federal Aging Research Initiative
Buck Institute aims to advance bioinformatics using Oracle Life Sciences Data Intelligence to transform aging research into a…
Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
AtaiBeckley’s lead program, BPL-003, is designed to provide durable relief from treatment-resistant depression Acquisition expands Lilly’s neuroscience pipeline…
Septa Pharmaceuticals Inc. Acquires CeeNU® (Lomustine) from Bristol Myers Squibb, Canada
Mississauga, ON, July 15, 2026 /PRNewswire/ – Septa Pharmaceuticals Inc., a rapidly growing leader in the Canadian healthcare…
BillionToOne’s Northstar Response® Is a Stronger Predictor of Immunotherapy Outcomes Than Standard-of-Care Imaging for Cancer Patients in Peer-Reviewed Study
Tissue-free ctDNA monitoring was the dominant independent predictor of survival across 12 tumor types and two prospective cohorts…
Bio Preventive Medicine and Precision Diabetes Announce ADA Late-Breaking Presentation Highlighting DNlite™ in Landmark CREDENCE Trial
New analysis supports DNlite™ for earlier renal risk stratification in patients with type 2 diabetes and chronic kidney…
Machine Learning Model Accurately Predicts Long-Term Risk of Type 2 Diabetes
Study of Over Three Million Patients for Risk of Type 2 Diabetes Demonstrates Potential for More Advanced Approach…
Novo Nordisk Introduces Extra Savings for Canadians Who Choose Ozempic®
MISSISSAUGA, ON, May 26, 2026 /CNW/ – Novo Nordisk Canada is announcing that effective Friday, May 29, 2026,…
Vi Launches Suite of AI Agents for Healthcare, Life Sciences, and Wellness Enterprises; Completes $145M Transaction at $1.64B Valuation
NEW YORK, May 19, 2026 /PRNewswire/ — Vi, the enterprise-AI platform for health, today announced a new suite…
Lilly’s Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials
In ATTAIN-MAINTAIN, participants who transitioned from a maximum tolerated dose (MTD) of Wegovy (semaglutide) to Foundayo maintained all…